Micronization enhances the protective effect of purified flavonoid fraction against postischaemic microvascular injury in the hamster cheek pouch.
1. The present study was designed to evaluate the effect of micronization on the protective effect of the purified flavonoid fraction (MPFF) on increases in macromolecular permeability induced by ischaemia-reperfusion in the hamster cheek pouch microcirculation. 2. Male hamsters (Mesocricetus auratus) were treated orally, twice a day, with vehicle (lactose), MPFF and non-micronized purified flavonoid fraction (PFF) at 5, 20, 80 and 320 mg/kg per day for 10 consecutive days. On the 11th day, cheek pouches of anaesthetized animals were prepared for intravital microscopy. 3. Local ischaemia was obtained by clamping the neck of the everted pouch and the increase in microvascular permeability was quantified as leakage (leaks) of intravenously injected fluorescein isothiocyanate-labelled dextran (FITC-dextran 150; MW = 150 000). 4. Reperfusion, after 30 min ischaemia, resulted in an immediate but reversible increase in post-capillary leakage. The MPFF induced a significant dose-related reduction in the increased permeability, with 83.4% inhibition compared with control at 320 mg/kg per day (19.2 +/- 1.9 vs 115.7 +/- 4.1 leaks/cm2; P < 0.0001). Non-micronized PFF was significantly less effective: only 47.9% inhibition compared with control was observed at 320 mg/kg per day (60.3 +/- 1.0 vs 115.7 +/- 4.1 leaks/cm2; P < 0.0001) and there was no dose-effect relationship. 5. In conclusion, micronization significantly enhances the protective effects of the purified flavonoid fraction on reperfusion injury in the hamster cheek pouch. This improvement is likely to be related to the better absorption of the micronized formulation, which could explain the superior clinical efficacy shown in previous studies.
Laboratório de Pesquisas em Microcirculação, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Fátima Z G A
FZ
Cyrino
Daniel A
DA
Bottino
Laurence
L
Lerond
Eliete
E
Bouskela
D000284:Administration, Oral; D000818:Animals; D002199:Capillary Permeability / Q000187:drug effects; D002610:Cheek / Q000098:blood supply*; D006224:Cricetinae; D004145:Diosmin / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D006569:Hesperidin / Q000008:administration & dosage / Q000494:pharmacology*; D007511:Ischemia / Q000150:complications / Q000503:physiopathology; D008297:Male; D008647:Mesocricetus; D008833:Microcirculation / Q000187:drug effects; D010316:Particle Size; D020011:Protective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D015424:Reperfusion; D015427:Reperfusion Injury / Q000517:prevention & control*
D004338:Drug Combinations; D020011:Protective Agents; D004145:Diosmin; D006569:Hesperidin